Lead optimization moves quickly. Your RNA supplier should too. Whether you're screening multiple constructs, evaluating doses, or advancing promising candidates, Aldevron's online store makes it easy to order the research grade mRNA you need, when you need it. Key benefits include: ��� Instant pricing with no sales process • Flexible quantities sized for your research stage • Faster turnaround enabled by cell-free DNA template production • Research grade material backed by extensive clinical manufacturing experience And when your program progresses? You're already working with a manufacturer trusted to support RNA programs from discovery through commercialization. Spend less time sourcing materials and more time generating data. Order now: https://ald.bio/4g89hSL What would make ordering RNA materials easier for your team? #mRNA #RNAResearch #RNATherapeutics #DrugDevelopment #Biotechnology #Aldevron
Aldevron
Biotechnology Research
Fargo, North Dakota 24,770 followers
A world where every cure is possible.
About us
Aldevron is proud to be part of Danaher. Danaher’s science and technology leadership puts Aldevron’s solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher’s other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.
- Website
-
http://www.aldevron.com
External link for Aldevron
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Fargo, North Dakota
- Type
- Privately Held
- Founded
- 1998
- Specialties
- Plasmid DNA, Messenger RNA (mRNA), Recombinant Proteins, CRISPR/Cas9, cGMP, GMP-Source, Gene Therapy, Cell Therapy, Vaccine Development, and Gene Editing
Locations
-
Primary
Get directions
4055 41st Ave S
Fargo, North Dakota 58104, US
-
Get directions
5602 Research Park Blvd
Suite 112
Madison, Wisconsin 53719, US
-
Get directions
3100 University Dr S
Fargo, North Dakota 58103, US
-
Get directions
152 Grove St
Waltham, Massachusetts 02453, US
Employees at Aldevron
Updates
-
During National Sickle Cell Awareness Month, we recognize the patients, families, caregivers, advocates, clinicians, and researchers working to advance understanding of sickle cell disease and improve the future of care. Last year, Aldevron welcomed Victoria Gray, the first person to have their cells edited using CRISPR for sickle cell disease, as part of our Advance Beyond symposium. Her story was a powerful reminder that scientific progress is ultimately measured by its impact on people and families. Victoria spoke about the realities of living with sickle cell disease, the hope that research can create, and the importance of continuing to expand access for patients who need it most. This month, we honor the resilience of the sickle cell community and the individuals whose experiences continue to inspire the pursuit of new discoveries and new possibilities. #NationalSickleCellAwarenessMonth #SickleCellDisease #SickleCellAwareness #PatientPerspective #GeneEditing #CellAndGeneTherapy #ResearchMatters #Aldevron
-
-
Scientific progress depends on more than technical expertise. It depends on environments where people can do their best work safely and confidently. On World Day for Safety and Health at Work, we celebrate the teams whose commitment to safety, quality, and operational excellence helps make innovation possible. Because when safety is embedded in every step, better outcomes follow. #WorldDayForSafetyAndHealthAtWork #SafetyCulture #OperationalExcellence #Biotech #Aldevron
-
-
How early is too early to start thinking about manufacturing? For gene-modified cell therapies, choices made during plasmid design can create advantages or challenges that persist all the way through commercialization. That's why it's critical to align vector design, critical materials, and cGMP manufacturing strategies from the beginning. Join us on September 8 to learn how organizations can improve continuity across development stages while supporting more reproducible and scalable outcomes. Discover: • The downstream impact of plasmid design decisions • Ways to reduce process variability • Strategies for scaling with confidence • How to bridge common gaps between development and manufacturing teams September 8, 2026 | 10:30 AM EDT / 4:30 PM CEST Save your spot: https://ald.bio/4fNVtxQ #CellAndGeneTherapy #GeneModifiedCellTherapy #PlasmidDesign #GMPManufacturing #Biotech #CDMO #AdvancedTherapies
-
Genome editing is evolving quickly. As the toolbox expands beyond CRISPR/Cas9, researchers have more opportunities, and more decisions, when selecting an editing strategy. A thoughtful discussion from Loren Schoch and Mollie Schubert on how the field is advancing and what factors may shape technology selection moving forward. #GenomeEditing #GeneEditing #CellAndGeneTherapy #Biotech
CRISPR/Cas9 transformed #genomeediting, but it's no longer the only option. Explore current approaches and key considerations to choosing the right tool with Mollie Schubert, senior innovation product manager at IDT, and Loren Schoch, VP gene editing therapeutics at Aldevron in SEQanswers: https://ow.ly/VJmC50ZFHPc
-
-
Plasmid DNA remains foundational to gene editing, but the vector design you choose can have a significant impact on expression, cell health, and scalability. Next-generation Nanoplasmid™ vectors were developed to address challenges associated with conventional plasmids through a minimal, antibiotic-free backbone designed to support stronger expression, improved cell viability, and gene editing performance. In our latest blog, explore how Nanoplasmid™ DNA is helping researchers advance scalable gene editing workflows and why plasmid design remains an important consideration as programs move from discovery toward clinical development. Read the blog now: https://ald.bio/4zGaOIw #GeneEditing #CellTherapy #GeneTherapy #PlasmidDNA #Nanoplasmid #BiotechInnovation #CellAndGeneTherapy #AdvancedTherapies #CRISPR #GenomeEditing
-
Aldevron reposted this
The path to successful gene-modified cell therapy starts long before commercialization. Join us on September 8 to learn how aligning plasmid design, critical materials, and cGMP manufacturing can help support more consistent, scalable outcomes throughout development, including: - How early plasmid design decisions influence downstream performance - Strategies to improve reproducibility and reduce variability - Key considerations for scaling from development to commercialization - Where disconnects commonly occur, and how to build a more connected workflow 🗓️ Save the date: September 8, 2026 | 10:30 AM EDT / 4:30 PM CEST Aldevron Register today: https://buff.ly/hOEEsV2
-
Your RNA workflow just got a lot simpler. For many research teams, ordering materials can create unnecessary delays. Waiting for quotes, exchanging emails to confirm specifications, and navigating procurement processes all add time before work can begin. Research grade mRNA is now available through Aldevron's online store, giving scientists more control over how they source RNA for their programs. Configure important specifications such as capping method, quantity, and endotoxin requirements, then place your order when it works for your timeline. Behind every order is a partner trusted for high-quality mRNA manufacturing since 2017, with the expertise to support programs from discovery through commercialization. The same quality you count on. Ordering that finally keeps pace with your research. Ready to get started? Explore research grade mRNA from Aldevron: https://ald.bio/4wXFGTl #mRNA #RNATherapeutics #BiotechResearch #LifeSciences #Aldevron
-
-
In gene-modified cell therapy, manufacturing success starts long before cGMP production. Decisions made during plasmid design can influence reproducibility, scalability, and overall program efficiency throughout development. Yet many organizations still approach vector design, critical materials, and manufacturing as separate activities. Join us on September 8 as industry experts discuss practical strategies for building a more connected workflow from early development through commercialization. Key discussion topics: ✅ How plasmid design impacts downstream performance ✅ Approaches to improve consistency and reduce variability ✅ Considerations for scaling manufacturing processes ✅ Common points of disconnect and how to address them September 8, 2026 | 10:30 AM EDT / 4:30 PM CEST Register today: https://ald.bio/3TDvDUN #CellTherapy #GeneModifiedCellTherapy #CGT #PlasmidDNA #Biomanufacturing #GMP #GeneEditing
-
How do you accelerate RNA capping process development without sacrificing analytical confidence? As mRNA-based vaccines and therapeutics advance, development teams need analytical workflows that can evaluate more samples, compare process conditions efficiently, and support faster decision-making. In this presentation, Rebecca Young explores how combining InDevR's VaxArray® 5'CapQ assay with HPLC-based methods can help streamline RNA capping process development. The approach pairs high-throughput analysis with detailed confirmation, providing valuable insight into capping efficiency and RNA integrity from early R&D through manufacturing readiness. Read the presentation highlights: https://ald.bio/4wrcEub #mRNA #RNATherapeutics #ProcessDevelopment #Bioprocessing #Biomanufacturing #AnalyticalDevelopment